These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38812619)

  • 1. Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients.
    Güler AA; Özçimen B; Aydoğdu MS; Sari A; Numune A; Ersan NT; Çolak S; Karadeniz H; Vasi İ; Küçük H; Yalçinkaya Y; Erden A; Kayaalp M; Öztürk MA; Göker B; Omma A; Yilmaz S; Koca SS; Inanç M; Akdoğan A; Tufan A
    Turk J Med Sci; 2024; 54(1):76-85. PubMed ID: 38812619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.
    de Oliveira SM; Martins LVO; Lupino-Assad AP; Medeiros-Ribeiro AC; de Moraes DA; Del-Rio APT; Oliveira MC; Sampaio-Barros PD; Kayser C
    Semin Arthritis Rheum; 2022 Aug; 55():151987. PubMed ID: 35286906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.
    Drake TM; Docherty AB; Harrison EM; Quint JK; Adamali H; Agnew S; Babu S; Barber CM; Barratt S; Bendstrup E; Bianchi S; Villegas DC; Chaudhuri N; Chua F; Coker R; Chang W; Crawshaw A; Crowley LE; Dosanjh D; Fiddler CA; Forrest IA; George PM; Gibbons MA; Groom K; Haney S; Hart SP; Heiden E; Henry M; Ho LP; Hoyles RK; Hutchinson J; Hurley K; Jones M; Jones S; Kokosi M; Kreuter M; MacKay LS; Mahendran S; Margaritopoulos G; Molina-Molina M; Molyneaux PL; O'Brien A; O'Reilly K; Packham A; Parfrey H; Poletti V; Porter JC; Renzoni E; Rivera-Ortega P; Russell AM; Saini G; Spencer LG; Stella GM; Stone H; Sturney S; Thickett D; Thillai M; Wallis T; Ward K; Wells AU; West A; Wickremasinghe M; Woodhead F; Hearson G; Howard L; Baillie JK; Openshaw PJM; Semple MG; Stewart I; Jenkins RG;
    Am J Respir Crit Care Med; 2020 Dec; 202(12):1656-1665. PubMed ID: 33007173
    [No Abstract]   [Full Text] [Related]  

  • 4. Case Report: Systemic Sclerosis After Covid-19 Infection.
    Fineschi S
    Front Immunol; 2021; 12():686699. PubMed ID: 34262566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
    Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
    Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
    Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
    Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data.
    Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
    Chron Respir Dis; 2023; 20():14799731231195041. PubMed ID: 37596992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
    Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
    Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.
    Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A
    Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The impact of COVID-19 in a cohort of patients with systemic sclerosis].
    Cruz-Domínguez MDP; Morales-Montalvo SI; Vera-Lastra OL; López-Zamora B; Ordoñez-González I; Medina-García G; López-Burgos CP; Montes-Cortés DH; Jara-Quezada LJ
    Rev Med Inst Mex Seguro Soc; 2023 Mar; 61(2):163-171. PubMed ID: 37201206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.
    Hoa S; Bernatsky S; Steele RJ; Baron M; Hudson M;
    Rheumatology (Oxford); 2020 May; 59(5):1108-1117. PubMed ID: 31535689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
    Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
    Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.
    Tomiyama F; Watanabe R; Ishii T; Kamogawa Y; Fujita Y; Shirota Y; Sugimura K; Fujii H; Harigae H
    Tohoku J Exp Med; 2016 Aug; 239(4):297-305. PubMed ID: 27487743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress.
    Orlandi M; Lepri G; Bruni C; Wang Y; Bartoloni A; Zammarchi L; Cometi L; Guiducci S; Matucci-Cerinic M; Bellando-Randone S
    Clin Rheumatol; 2020 Jul; 39(7):2043-2047. PubMed ID: 32514674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States.
    Fan Y; Bender S; Shi W; Zoz D
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1539-1547. PubMed ID: 32996805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit.
    Suleyman G; Fadel RA; Malette KM; Hammond C; Abdulla H; Entz A; Demertzis Z; Hanna Z; Failla A; Dagher C; Chaudhry Z; Vahia A; Abreu Lanfranco O; Ramesh M; Zervos MJ; Alangaden G; Miller J; Brar I
    JAMA Netw Open; 2020 Jun; 3(6):e2012270. PubMed ID: 32543702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial lung disease in South Africans with systemic sclerosis.
    Ashmore P; Tikly M; Wong M; Ickinger C
    Rheumatol Int; 2018 Apr; 38(4):657-662. PubMed ID: 29185086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study.
    Knarborg M; Løkke A; Hilberg O; Ibsen R; Sikjaer MG
    Respirology; 2022 May; 27(5):341-349. PubMed ID: 35224821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.